MX2021002450A - Ensayo de cribado de cáncer inmunogenético. - Google Patents

Ensayo de cribado de cáncer inmunogenético.

Info

Publication number
MX2021002450A
MX2021002450A MX2021002450A MX2021002450A MX2021002450A MX 2021002450 A MX2021002450 A MX 2021002450A MX 2021002450 A MX2021002450 A MX 2021002450A MX 2021002450 A MX2021002450 A MX 2021002450A MX 2021002450 A MX2021002450 A MX 2021002450A
Authority
MX
Mexico
Prior art keywords
immunogenetic
screening test
cancer screening
cancer
risk
Prior art date
Application number
MX2021002450A
Other languages
English (en)
Inventor
József Toth
Orsolya Lorincz
Eszter Somogyi
Mónika Megyesi
Eniko Toke
Julianna Liszewicz
Levente Molnar
Zsolt Csiszovszk
Katalin Pantya
Péter Páles
István Miklós
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of MX2021002450A publication Critical patent/MX2021002450A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

La divulgación se refiere a un método para determinar el riesgo de que un sujeto humano desarrolle un cáncer, el procedimiento comprende la cuantificación de los tripletes HLA (HEAT) del sujeto que son capaces de unirse a epítopos de células T en la secuencia de aminoácidos de antígenos asociados a tumores. La divulgación también se refiere a procedimientos de tratamiento de sujetos a los que se ha determinado que tienen un riesgo elevado de desarrollar cáncer.
MX2021002450A 2018-09-04 2019-09-03 Ensayo de cribado de cáncer inmunogenético. MX2021002450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1814361.0A GB201814361D0 (en) 2018-09-04 2018-09-04 Immunogenetic cancer screening test
PCT/EP2019/073478 WO2020048992A1 (en) 2018-09-04 2019-09-03 Immunogenetic cancer screening test

Publications (1)

Publication Number Publication Date
MX2021002450A true MX2021002450A (es) 2021-07-15

Family

ID=63920791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002450A MX2021002450A (es) 2018-09-04 2019-09-03 Ensayo de cribado de cáncer inmunogenético.

Country Status (18)

Country Link
US (1) US20220233660A1 (es)
EP (1) EP3847461A1 (es)
JP (1) JP7419351B2 (es)
KR (1) KR20210086611A (es)
CN (1) CN113330313A (es)
AU (1) AU2019333861A1 (es)
BR (1) BR112021004079A2 (es)
CA (1) CA3110918A1 (es)
CL (1) CL2021000533A1 (es)
CO (1) CO2021004035A2 (es)
EA (1) EA202190671A1 (es)
GB (1) GB201814361D0 (es)
IL (1) IL281218A (es)
MA (1) MA53542A (es)
MX (1) MX2021002450A (es)
SG (1) SG11202101956VA (es)
WO (1) WO2020048992A1 (es)
ZA (1) ZA202101549B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010460A (es) 2017-03-03 2020-01-09 Treos Bio Zrt Plataforma de identificacion de peptidos inmunogenicos basada en poblacion.
JP2021536487A (ja) 2018-09-04 2021-12-27 トレオス バイオ リミテッド ペプチドワクチン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
AU2014298504B2 (en) 2013-07-30 2018-08-30 Biontech Ag Tumor antigens for determining cancer therapy
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
MX2019010460A (es) 2017-03-03 2020-01-09 Treos Bio Zrt Plataforma de identificacion de peptidos inmunogenicos basada en poblacion.
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine

Also Published As

Publication number Publication date
AU2019333861A1 (en) 2021-03-18
EA202190671A1 (ru) 2021-09-21
IL281218A (en) 2021-04-29
BR112021004079A2 (pt) 2021-05-25
CA3110918A1 (en) 2020-03-12
SG11202101956VA (en) 2021-03-30
KR20210086611A (ko) 2021-07-08
CL2021000533A1 (es) 2021-09-24
CO2021004035A2 (es) 2021-07-30
WO2020048992A1 (en) 2020-03-12
EP3847461A1 (en) 2021-07-14
US20220233660A1 (en) 2022-07-28
GB201814361D0 (en) 2018-10-17
ZA202101549B (en) 2024-08-28
JP7419351B2 (ja) 2024-01-22
CN113330313A (zh) 2021-08-31
JP2022500630A (ja) 2022-01-04
MA53542A (fr) 2021-07-14

Similar Documents

Publication Publication Date Title
ZA202101549B (en) Immunogenetic cancer screening test
UY38049A (es) Anti-pd-1 anticuerpos y métodos de tratamiento
PH12020551211A1 (en) Antibodies binding to gprc5d
CR20210325A (es) Anticuerpos que se unen a cd3
CY1123556T1 (el) Αντισωμα που δεσμευει τις erbb-2 και erbb-3
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
MX2017013777A (es) Metodo para el tratamiento de cancer.
BR112018070159A2 (pt) moléculas de ligação de bcma e métodos de uso das mesmas
ZA201904723B (en) Population-based immunogenic peptide identification platform
EA201991385A1 (ru) Анти-gpc3-антитело
CR20220019A (es) Anticuerpos que se fijan a gprc5d
BR112021024540A2 (pt) Métodos para selecionar uma célula ou um vírus, determinar a sequência de um ácido nucleico, produzir uma célula que expressa um ácido nucleico e tratar um sujeito, célula imune selecionada e método para selecionar uma célula imune
EA201792679A1 (ru) Способы диагностики и лечения злокачественной опухоли
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
CL2021002008A1 (es) Proteinas de unión de antígeno del receptor gamma anti-il2.
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
NZ733097A (en) Fcrn antibodies and methods of use thereof
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
EA201590187A1 (ru) Моноклональные антитела для применения в диагностике и терапии злокачественных опухолей и аутоиммунного заболевания
NZ738875A (en) Motile sperm domain containing protein 2 and cancer
BR112018008799A2 (pt) método de prognóstico